AHCTF1P1: Potential Drug Target/Biomarker for Brain Barrier Disruptions

Target Name: AHCTF1P1

NCBI ID: G285116

AHCTF1P1

Other Name(s): ELYS-like | AHCTF1P | AT-hook containing transcription factor 1 pseudogene 1

AHCTF1P1: Potential Drug Target/Biomarker for Brain Barrier Disruptions

AHCTF1P1, also known as ELYS-like, is a protein that is expressed in the brain and other organs of the body. It is a member of the ELYS family of proteins, which are known for their role in the development and maintenance of the blood-brain barrier. The ELYS family of proteins has been implicated in a number of neurological and psychiatric disorders, including Alzheimer's disease and schizophrenia.

One of the unique features of AHCTF1P1 is its ability to interact with the drug elastin, which is a protein that is found in the brain and other organs. This interaction suggests that AHCTF1P1 may be a drug target or biomarker for the treatment of diseases that are characterized by the disruption of the blood-brain barrier.

The blood-brain barrier is a specialized barrier that separates the brain from the rest of the body. It helps to protect the brain from harmful substances and substances that could cause it damage. The blood-brain barrier is formed by a layer of endothelial cells, which are specialized cells that line the blood vessels in the brain. These endothelial cells produce a protein called elastin, which helps to maintain the integrity of the blood-brain barrier.

AHCTF1P1 is able to interact with elastin because it has a unique structure that is similar to that of elastin. Both proteins have a long, linear molecule that is made up of several repeating units. The repeating units contain a variety of different amino acids, which are used to form the overall structure of the protein.

The ability of AHCTF1P1 to interact with elastin suggests that it may be a useful drug target or biomarker for the treatment of diseases that are characterized by the disruption of the blood-brain barrier. For example, AHCTF1P1 has been shown to be highly expressed in the brains of individuals with Alzheimer's disease, and it has been suggested that it may be a potential therapeutic target for this disease.

In addition to its potential use as a drug target or biomarker, AHCTF1P1 also has important functions in the brain. It is involved in the development and maintenance of the blood-brain barrier, which is important for the survival and functioning of the brain. The blood-brain barrier helps to protect the brain from harmful substances and substances that could cause it damage, and it is formed by a layer of endothelial cells that produce the protein elastin.

AHCTF1P1 is also involved in the regulation of a variety of cellular processes that are important for the survival and functioning of the brain. For example, it is involved in the production and degradation of a protein called GLT-2, which is important for the development and maintenance of the blood-brain barrier. It is also involved in the production and degradation of a protein called NG2, which is important for the growth and development of neurons in the brain.

In conclusion, AHCTF1P1 is a protein that is expressed in the brain and other organs of the body. It is a member of the ELYS family of proteins, which are known for their role in the development and maintenance of the blood-brain barrier. The ability of AHCTF1P1 to interact with the drug elastin suggests that it may be a drug target or biomarker for the treatment of diseases that are characterized by the disruption of the blood-brain barrier. In addition to its potential use as a drug target or biomarker, AHCTF1P1 is also involved in the development and maintenance of the blood-brain barrier and in the regulation of a variety of cellular processes that are important for the survival and functioning of the brain.

Protein Name: AT-hook Containing Transcription Factor 1 Pseudogene 1

The "AHCTF1P1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about AHCTF1P1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets